Science News
from research organizations

Chemoradiotherapy vs. chemotherapy for locally advanced pancreatic cancer

Date:
May 3, 2016
Source:
The JAMA Network Journals
Summary:
Researchers have assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after four months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival. Gemcitabine and erlotinib are drugs used to treat cancer.
Share:
FULL STORY

In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival. Gemcitabine and erlotinib are drugs used to treat cancer.

In locally advanced pancreatic cancer, the role of chemoradiotherapy is controversial and the efficacy of erlotinib is unknown. For this study, the researchers first randomly assigned 449 patients to receive gemcitabine alone (n = 223) and 219 patients received gemcitabine plus erlotinib. In the second randomization involving patients with progression-free disease after 4 months, 136 patients received 2 months of the same chemotherapy and 133 underwent chemoradiotherapy (54 Gy [a measure of radiation dose] plus the chemotherapy drug capecitabine).

A total of 442 of the 449 patients enrolled underwent the first randomization. Of these, 269 underwent the second randomization. With a median follow-up of 36.7 months, the researchers found no survival benefit of chemoradiotherapy compared with chemotherapy, with median overall survival from the date of the first randomization of 15.2 months and 16.5 months, respectively. Also, there was no significant difference in overall survival with gemcitabine (13.6 months) compared with gemcitabine plus erlotinib (11.9 months).


Story Source:

Materials provided by The JAMA Network Journals. Note: Content may be edited for style and length.


Journal Reference:

  1. Pascal Hammel, Florence Huguet, Jean-Luc van Laethem, David Goldstein, Bengt Glimelius, Pascal Artru, Ivan Borbath, Olivier Bouché, Jenny Shannon, Thierry André, Laurent Mineur, Benoist Chibaudel, Franck Bonnetain, Christophe Louvet. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib. JAMA, 2016; 315 (17): 1844 DOI: 10.1001/jama.2016.4324

Cite This Page:

The JAMA Network Journals. "Chemoradiotherapy vs. chemotherapy for locally advanced pancreatic cancer." ScienceDaily. ScienceDaily, 3 May 2016. <www.sciencedaily.com/releases/2016/05/160503131349.htm>.
The JAMA Network Journals. (2016, May 3). Chemoradiotherapy vs. chemotherapy for locally advanced pancreatic cancer. ScienceDaily. Retrieved May 27, 2017 from www.sciencedaily.com/releases/2016/05/160503131349.htm
The JAMA Network Journals. "Chemoradiotherapy vs. chemotherapy for locally advanced pancreatic cancer." ScienceDaily. www.sciencedaily.com/releases/2016/05/160503131349.htm (accessed May 27, 2017).

RELATED STORIES